Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4VADN)

Drug Name
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Drug Info
Synonyms CHEMBL575896; N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10155934
TTD Drug ID
DM4VADN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Matrix metalloproteinase-12 (MMP-12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [2]
FP-025 DMH1NXO Asthma CA23 Phase 1 [3]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [4]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
AZD1236 DML3RSF Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [6]
V85546 DMLFMSY Inflammation 1A00-CA43.1 Discontinued in Phase 1 [7]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-8 (MMP-8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [9]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [10]
SC-44463 DMBPNKT N. A. N. A. Terminated [11]
BB-1101 DM7GH5Z Multiple sclerosis 8A40 Terminated [12]
MMI270 DM38N2K Discovery agent N.A. Investigative [13]
IK-862 DMJA4UE Discovery agent N.A. Investigative [14]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [1]
SL422 DM3I2US Discovery agent N.A. Investigative [15]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [1]
Ro-37-9790 DM83QMZ Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-13 (MMP-13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [17]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [18]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [19]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [4]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [4]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [20]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [22]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [23]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [24]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [25]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [26]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [2]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [4]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-14 (MMP-14)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [27]
BT1718 DMTXBUV Solid tumour/cancer 2A00-2F9Z Phase 1/2a [28]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [29]
MMI270 DM38N2K Discovery agent N.A. Investigative [30]
IK-862 DMJA4UE Discovery agent N.A. Investigative [14]
SR-973 DMU48OD Discovery agent N.A. Investigative [31]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [1]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [1]
UK-356618 DM02FGH Discovery agent N.A. Investigative [32]
PMID23631440C29e DMM92IB Discovery agent N.A. Investigative [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-2 (MMP-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [34]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [27]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [35]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [2]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [36]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [4]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [4]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-21 (MMP-21)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
IK-862 DMJA4UE Discovery agent N.A. Investigative [14]
SR-973 DMU48OD Discovery agent N.A. Investigative [31]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [1]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [1]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT Discovery agent N.A. Investigative [5]
N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ Discovery agent N.A. Investigative [37]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-12 (MMP-12) TTXZ0KQ MMP12_HUMAN Inhibitor [1]
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]
Matrix metalloproteinase-14 (MMP-14) TTJ4QE7 MMP14_HUMAN Inhibitor [1]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [1]
Matrix metalloproteinase-21 (MMP-21) TTYRF5E MMP21_HUMAN Inhibitor [1]
Matrix metalloproteinase-8 (MMP-8) TTGA1IV MMP8_HUMAN Inhibitor [1]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [1]

References

1 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
2 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
3 Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
4 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
5 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Clinical pipeline report, company report or official report of Vernalis.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
10 Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995).
11 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
12 New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908.
13 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62.
14 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
15 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
16 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
17 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
18 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
19 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
20 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
21 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
22 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
23 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
24 National Cancer Institute Drug Dictionary (drug id 747683).
25 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
26 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
27 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
28 ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
29 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
30 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
31 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
32 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
33 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
34 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
35 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
36 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
37 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.